Another mono-directed GLP-1 agonist, semaglutide, also primarily developed for the treatment of type 2 diabetes, has shown promising results in reducing bodyweight in obese individuals with diabetes and resulted in a reduction of CVD events in patients with obesity but without diabetes [67–69]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.